Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of on-demand GSK557296 for premature ejaculation
2009-011855-40Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of epelsiban in premature ejaculation (PE) (3 arms), sponsored by GSK. Primary endpoint: Intravaginal ejaculatory latency time. Started Oct 2009; status: completed.
02
Drugs
epelsiban
03
Conditions
premature ejaculation (PE)
Beyond the preview
Go deeper on 2009-011855-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011855-40.